10-Q: Tvardi Therapeutics Completes Merger with Cara Therapeutics, Announces Q1 2025 Financial Results

Tvardi Therapeutics, formerly Cara Therapeutics, reports its first quarterly results post-merger, highlighting financial details and strategic shifts.

Summary

• Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., completed its merger on April 15, 2025.
• The company is now focused on developing oral, small molecule therapies targeting STAT3 for fibrosis-driven diseases.
• The lead product candidate, TTI-101, is in Phase 2 clinical development for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
• A second product candidate, TTI-109, is also an oral STAT3 inhibitor, with an Investigational New Drug application expected in the first half of 2025.
• The Q1 2025 financial results reflect Cara's operations prior to the merger.
• Revenue for the three months ended March 31, 2025, was $2.569 million, compared to $2.135 million for the same period in 2024.
• Net loss for Q1 2025 was $(4.906) million, or $(3.22) per share, compared to $(30.696) million, or $(20.24) per share, for Q1 2024.
• Research and development expenses decreased significantly to $319,000 from $21.964 million year-over-year due to discontinuation of clinical programs.
• As of March 31, 2025, cash and cash equivalents totaled $34.217 million.
• The company expects to continue incurring significant operating losses and will need additional funding to advance its research and development activities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, the significant decrease in net loss and R&D expenses indicates improved financial management. The completion of the merger and focus on promising therapies also contribute to a cautiously optimistic outlook.

Positives

• Revenue increased to $2.569 million in Q1 2025 from $2.135 million in Q1 2024.
• Net loss significantly decreased to $(4.906) million in Q1 2025 from $(30.696) million in Q1 2024.
• Research and development expenses decreased substantially to $319,000 from $21.964 million year-over-year.
• The company has $34.217 million in cash and cash equivalents as of March 31, 2025.

Negatives

• The company incurred a net loss of $(4.906) million for Q1 2025.
• The company expects to continue incurring significant operating losses.
• The company will need additional funding to advance its research and development activities.
• Legacy Tvardi identified material weaknesses in its internal control over financial reporting, and, following the Merger, such material weaknesses must be remediated by the Company.

Risks

• The company's ability to achieve profitability is dependent on its ability to successfully develop its lead compound, conduct clinical trials, obtain regulatory approvals, and support commercialization activities for its product candidates.
• The company's product candidates are still in the early stages of development, and substantial additional financing will be needed by the company to fund its operations and ongoing research and development efforts prior to the commercialization of its product candidates.
• The company's ability to access capital when and in the amount needed is not assured.
• The company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all.
• The company may be subject to legal proceedings and claims arising in the ordinary course of its business.

Future Outlook

The company expects to continue incurring significant operating losses and will need additional funding to advance its research and development activities. Tvardi expects to report unblinded data from its Phase 2 IPF clinical trial in the second half of 2025 and anticipates preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026. Tvardi expects to submit an Investigational New Drug application for TTI-109 in the first half of 2025.

Industry Context

The announcement reflects a strategic shift in the biopharmaceutical industry, with companies like Tvardi focusing on targeted therapies for specific diseases. The merger allows for a more focused approach to drug development and potential commercialization.

Comparison to Industry Standards

• It is difficult to compare Tvardi's results directly to industry standards due to its unique focus and stage of development.
• Comparable companies in the clinical-stage biopharmaceutical sector include Morphic Therapeutics Inc. and Scholar Rock Inc., which are also developing therapies for fibrosis-driven diseases.
• However, direct comparisons are limited by differences in pipeline stage, therapeutic targets, and financial structures.
• The decrease in R&D spending is consistent with a company streamlining operations after a strategic shift, which is a common practice in the industry.

Management Changes

Legal Proceedings

• Two lawsuits were filed in the Supreme Court of the State of New York, County of New York, on March 5 and March 6, 2025 by two purported stockholders of Cara in connection with the Merger.
• Between December 20, 2024 and March 19, 2025, Cara received thirteen demands and three draft complaints from purported stockholders of Cara making substantially similar allegations as in the Complaints regarding the disclosures in the Proxy Statement/Prospectus related to the Merger and assert claims for violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934.

Related Party Transactions

• As of March 31, 2025, Vifor International owned 205,465, or 13.5%, of Caras common stock.
• CSL Vifor and its affiliates are considered related parties as of March 31, 2025 and December 31, 2024.
• Amounts due from CSL Vifor were $1.229 million as of March 31, 2025, primarily relating to profit-sharing revenue from sales of KORSUVA injection in the United States.
• Collaborative revenue of $1.198 million from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders: The merger and strategic shift aim to maximize shareholder value, but the company's future success is uncertain.
• Employees: Workforce reductions have impacted employees, but the new focus may create new opportunities.
• Patients: The development of new therapies targeting STAT3 could provide new treatment options for fibrosis-driven diseases.
• Suppliers: The company's reliance on third-party manufacturers and suppliers means their performance is critical to its success.

Next Steps

• Report unblinded data from its Phase 2 IPF clinical trial in the second half of 2025.
• Anticipate preliminary topline data from its Phase 1b/2 HCC clinical trial in the first half of 2026.
• Submit an Investigational New Drug application for TTI-109 in the first half of 2025.

Key Dates

Keywords

Tvardi Therapeutics, merger, Cara Therapeutics, STAT3, TTI-101, TTI-109, IPF, HCC, clinical trials, biopharmaceutical, financial results